9 results
424B3
IMNM
Immunome, Inc.
28 Aug 23
Prospectus supplement
9:10am
up to 90 percent of the gross tumor mass, leaving original tumor cells in the minority. Many CAFs differ from normal fibroblasts by their expression
S-4/A
IMNM
Immunome, Inc.
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
, and extracellular fibrosis can contribute up to 90 percent of the gross tumor mass, leaving original tumor cells in the minority. Many CAFs differ from normal
S-4
IMNM
Immunome, Inc.
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
of the gross tumor mass, leaving original tumor cells in the minority. Many CAFs differ from normal fibroblasts by their expression of FAP
10-K
2020 FY
IMNM
Immunome, Inc.
25 Mar 21
Annual report
5:01pm
, Merck & Co. Inc., AstraZeneca plc, or AstraZeneca, and F. Hoffmann-La Roche Ltd. However, these immuno-therapeutics are effective in only a minority
424B4
joa2idyr9mdinyc
5 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
xcwuiaidci z4r
24 Sep 20
IPO registration (amended)
7:18am
S-1
2mszsix0wwgi76
9 Sep 20
IPO registration
4:19pm
DRS
d43tqg
12 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next